OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Litton on Activity of Talazoparib in Advanced BRCA1/2+ Breast Cancer

May 19th 2020

Jennifer Litton, MD, discusses the findings from the overall survival analysis of the EMBRACA trial, the implications of these data, and the future utility of talazoparib in this space.

Dr. Smith on Ongoing Research in Relapsed/Refractory MCL

May 18th 2020

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Dr. Dimou on Emerging Treatment Options in BRAF+ Lung Cancer

May 18th 2020

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

May 18th 2020

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

May 18th 2020

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Dr. Dimou on Emerging Treatment Options in BRAF+ Lung Cancer

May 18th 2020

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Dr. Smith on Ongoing Research in Relapsed/Refractory MCL

May 18th 2020

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Dr. Yee on Trials Evaluating Treatment in Lenalidomide-Refractory Multiple Myeloma

May 18th 2020

Andrew Yee, MD, discusses trials evaluating treatment for patients with lenalidomide-refractory multiple myeloma.

Dr. Donington on the Role of Neoadjuvant Immunotherapy in Stage II NSCLC

May 16th 2020

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer.

Dr. Wang on Research Trends in MCL

May 16th 2020

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Dr. Koo on the Need for Next-Generation Imaging in Prostate Cancer

May 16th 2020

Phillip J. Koo, MD, discusses the need for next-generation imaging in prostate cancer.

Dr. Vargas on Research With Proton Therapy in Prostate Cancer

May 16th 2020

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

Dr. Tsao on Improving Outcomes in RCC

May 16th 2020

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Dr. O'Donnell on Up-front Triplets in Multiple Myeloma

May 16th 2020

Betsy O'Donnell, MD, discusses the utility of up-front triplet regimens in multiple myeloma.

Dr. Lilenbaum on the Rise of Immunotherapy in NSCLC

May 16th 2020

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.

Dr. Donington on the Role of Neoadjuvant Immunotherapy in Stage II NSCLC

May 15th 2020

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer.

Dr. Chaft on Immune-Related AEs in NSCLC

May 15th 2020

Jamie E. Chaft, MD, discusses immune-related adverse effects in non–small cell lung cancer.

Dr. Lilenbaum on the Rise of Immunotherapy in NSCLC

May 15th 2020

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.

CLR 131 Mechanism of Action

May 15th 2020

Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC

May 15th 2020

Gilberto De Lima Lopes, MD, discusses the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) in non–small cell lung cancer (NSCLC).